The US Food and Drug Administration (FDA) has told Moderna (Nasdaq: MRNA) that it will need more time to complete its assessment of the Emergency Use Authorization (EUA) request for the use of the company’s COVID-19 vaccine at the 100µg dose level in adolescents aged 12 to 17 years.
On Friday evening, the FDA informed Moderna that the agency requires additional time to evaluate recent international analyses of the risk of myocarditis after vaccination.
The agency told the company that this review may not be completed before January 2022.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze